2024. Bimekizumab 3-year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from Five Phase 3/3b Trials. SKIN The Journal of Cutaneous Medicine. 8, 1 (Jan. 2024), s305. DOI:https://doi.org/10.25251/skin.8.supp.305.